Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Ritchie

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Oncoimmunology|November 21, 2015
CAR-T cells are serial killersAlexander J Davenport, Misty R Jenkins, David S Ritchie, et al.
British Journal of Haematology|August 22, 2009
Mantle cell lymphoma with central nervous system involvement: frequency and clinical featuresSaar Gill, Kirsten E Herbert, H Miles Prince, et al.
Nature Immunology|March 25, 2014
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functionsChristopher J Chan, Ludovic Martinet, Susan Gilfillan, et al.
Blood|May 1, 2012
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cellsSaar Gill, Adrianne E Vasey, Alysha De Souza, et al.
British Journal of Haematology|July 18, 2024
Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemiaAshvind Prabahran, Jibran Durrani, Juan Coelho-Da Silva, et al.
Blood|September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaSimon J Harrison, Hang Quach, Emma Link, et al.
Cancer Immunology Research|February 26, 2015
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target CellsAlexander J Davenport, Misty R Jenkins, Ryan S Cross, et al.
Leukemia & Lymphoma|July 5, 2013
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantSimon J Harrison, Andy K Hsu, Paul Neeson, et al.
Blood Advances|October 8, 2020
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyJoanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, et al.
Blood Neoplasia|November 24, 2025
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FLRachel M Koldej, Allison Barraclough, Huw Morgan, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Oncoimmunology|November 21, 2015
CAR-T cells are serial killersAlexander J Davenport, Misty R Jenkins, David S Ritchie, et al.
British Journal of Haematology|August 22, 2009
Mantle cell lymphoma with central nervous system involvement: frequency and clinical featuresSaar Gill, Kirsten E Herbert, H Miles Prince, et al.
Nature Immunology|March 25, 2014
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functionsChristopher J Chan, Ludovic Martinet, Susan Gilfillan, et al.
Blood|May 1, 2012
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cellsSaar Gill, Adrianne E Vasey, Alysha De Souza, et al.
British Journal of Haematology|July 18, 2024
Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemiaAshvind Prabahran, Jibran Durrani, Juan Coelho-Da Silva, et al.
Blood|September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaSimon J Harrison, Hang Quach, Emma Link, et al.
Cancer Immunology Research|February 26, 2015
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target CellsAlexander J Davenport, Misty R Jenkins, Ryan S Cross, et al.
Leukemia & Lymphoma|July 5, 2013
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantSimon J Harrison, Andy K Hsu, Paul Neeson, et al.
Blood Advances|October 8, 2020
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyJoanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, et al.
Blood Neoplasia|November 24, 2025
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FLRachel M Koldej, Allison Barraclough, Huw Morgan, et al.
Pageof 10